nice change, page-23

Hey guys,

I have invested in this company since Joseph Gutnick was ousted as chairman and when the company was called Autogen.

A lot of water has gone under the bridge, but I kept investing and building my stake and referring friends to this wonderful company which is not only doing wonderful things for the customers it serves but for its supporters should they stay on and realise the full potential of the team and products that Greg Collier has assembled.

If you do back of the envelope sums you could conservatively value this team and its products at $5.00 ps. However, what we have here, is the vehicle that can deliver further discoveries and acquisitions and inevitably substantially greater shareholder wealth. Insead of contemplating whether to sell, investors could well be advised to buy more stock at these cheap prices. A lot of good news are yet to be released and I am patiently building my stake, even at these low prices.

Should a predator emerge, they would have to pay a hefty premium to extricate the shares from me, my supporters and not to mention the substantial shareholders who invested in Greg's team for the right reasons.

This is a company which should be allowed to extract its full potential.

Attached is a shortcut to "susans story" a lady who benefited from omacetaxine treatment, and also to Marc Sinatra's commentary on CXS in biotech daily:

http://leukemia.about.com/b/2008/10/22/susans-story.htm

http://www.biotechdaily.com.au/media/backissues/2009%20September/BD%20Biotech%20Daily%20September%209.pdf



DYOR